REPL - レプリミュ―ン (Replimune Group Inc.) レプリミュ―ン

 REPLのチャート


 REPLの企業情報

symbol REPL
会社名 Replimune Group Inc (レプリミュ―ン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Replimune Group Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP RP2 and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate RP1 in approximately 150 patients with a range of solid tumors.   レプリミュ―ンは米国のバイオ医薬品企業。臨床段階で、がん治療における腫瘍崩壊性免疫療法の開発に従事する。同社は独自の「Immulytic」プラットフォ―ムを使用して、固形腫瘍に対する患者の免疫システムを最大限に活性化させることを目的とする医薬品候補を開発する。本社所在地はマサチュ―セッツ州ウォ―バ―ン。   
本社所在地 18 Commerce Way Woburn MA 01801 USA
代表者氏名
代表者役職名
電話番号 +1 781-995-2443
設立年月日 42917
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 44人
url www.replimune.com
nasdaq_url https://www.nasdaq.com/symbol/repl
adr_tso
EBITDA EBITDA(百万ドル) -21.81300
終値(lastsale) 12.41
時価総額(marketcap) 391581069.52
時価総額 時価総額(百万ドル) 366.33810
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 400.67010
当期純利益 当期純利益(百万ドル) -26.19400
決算概要 決算概要 BRIEF: For the three months ended 30 June 2018 Replimune Group Inc revenues was not reported. Net loss increased from $3.6M to $10M. Higher net loss reflects Other Non Operating I/E increase from $0K to $5.5M (expense) Research and development increase of 68% to $3.8M (expense) General and administrative increase from $861K to $1.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.12 to -$0.32.

 REPLのテクニカル分析


 REPLのニュース

   Insider Selling: Replimune Group, Inc. (NASDAQ:REPL) COO Sells 30,000 Shares of Stock  2021/03/18 08:16:44 Watchlist News
Replimune Group, Inc. (NASDAQ:REPL) COO Colin Love sold 30,000 shares of the stock in a transaction dated Monday, March 15th. The stock was sold at an average price of $33.54, for a total value of $1,006,200.00. Following the transaction, the chief operating officer now owns 905,142 shares in the company, valued at $30,358,462.68. The transaction […]
   3 Biotech Stocks That Could Double In 12 Months  2021/03/17 13:15:17 Benzinga
Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by careful scrutiny and analysis — of a company's pipeline, collaborations, fundamentals, key make-or-break events and cash runway — can fetch disproportionate returns. Here are three biopharma stocks that have the potential to more than double from current levels: Immatics (NASDAQ: IMTX ) FibroGen, Inc. (NASDAQ: FGEN ) Replimune Group, Inc. (NASDAQ: REPL ) Immatics: Immatics is a clinical-stage biopharma engaged in the discovery and development of T cell directing cancer immunotherapies. The shares of the German biotech were listed on the Nasdaq in July 2020 following its business combination with Arya Sciences Acquisition Corp, a SPAC sponsored by Perceptive Advisors. The Pipeline: The company's T cell receptor (TCR)-based immunotherapies offer a targeted therapy to patients with high medical need. It has two lead product classes, namely engineered Adoptive Cell Therapies, or ACTengine, and antibody-like TCR Bispecifics, or TCER.
   Insider Selling: Replimune Group, Inc. (NASDAQ:REPL) CEO Sells 25,000 Shares of Stock  2021/01/20 05:58:41 Watchlist News
Replimune Group, Inc. (NASDAQ:REPL) CEO Philip Astley-Sparke sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, January 14th. The shares were sold at an average price of $44.42, for a total value of $1,110,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,287,845 shares of […]
   H.C. Wainwright Stick to Their Buy Rating for Replimune Group Inc By Investing.com  2021/01/06 11:15:33 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Replimune Group Inc
   H.C. Wainwright Stick to Their Buy Rating for Replimune Group Inc  2020/11/10 11:51:36 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Replimune Group Inc
   Insider Selling: Replimune Group, Inc. (NASDAQ:REPL) CEO Sells 25,000 Shares of Stock  2021/01/20 05:58:41 Watchlist News
Replimune Group, Inc. (NASDAQ:REPL) CEO Philip Astley-Sparke sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, January 14th. The shares were sold at an average price of $44.42, for a total value of $1,110,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,287,845 shares of […]
   H.C. Wainwright Stick to Their Buy Rating for Replimune Group Inc By Investing.com  2021/01/06 11:15:33 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Replimune Group Inc
   H.C. Wainwright Stick to Their Buy Rating for Replimune Group Inc  2020/11/10 11:51:36 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Replimune Group Inc
   The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping  2020/11/05 12:54:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbott Laboratories (NYSE: ABT ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Ascendis Pharma A/S (NASDAQ: ASND ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) Cardiff Oncology Inc (NASDAQ: CRDF ) Denali Therapeutics Inc (NASDAQ: DNLI ) - moved in sympathy with Biogen Inc (NASDAQ: BIIB ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inspire Medical Systems Inc (NYSE: INSP ) Immunovant Inc (NASDAQ: IMVT ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Laboratory Corp.
   The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO  2020/10/23 11:26:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Kodiak Sciences Inc (NASDAQ: KOD ) Nevro Corp (NYSE: NVRO ) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Repligen Corporation (NASDAQ: RGEN ) Replimune Group Inc (NASDAQ: REPL ) (priced its common stock offering of 4.69 million shares at $40 apiece. Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 22) Artelo Biosciences Inc (NASDAQ: ARTL ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Aziyo Biologics Inc (NASDAQ: AZYO ) DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its $15 million worth of common stock offering) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Metacrine Inc (NASDAQ: MTCR ) Rockwell Medical Inc (NASDAQ: RMTI ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Stocks In Focus Akebia Presents Positive Phase 3 Data For Anemia Drug In Chronic Kidney Disease Patients Akebia Therapeutics Inc (NASDAQ: AKBA ) presented at the American Society of Nephrology Kidney Week 2020 Reimagined, …
   H.C. Wainwright Stick to Their Buy Rating for Replimune Group Inc By Investing.com  2021/01/06 11:15:33 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Replimune Group Inc
   H.C. Wainwright Stick to Their Buy Rating for Replimune Group Inc  2020/11/10 11:51:36 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Replimune Group Inc
   The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping  2020/11/05 12:54:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbott Laboratories (NYSE: ABT ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Ascendis Pharma A/S (NASDAQ: ASND ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) Cardiff Oncology Inc (NASDAQ: CRDF ) Denali Therapeutics Inc (NASDAQ: DNLI ) - moved in sympathy with Biogen Inc (NASDAQ: BIIB ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inspire Medical Systems Inc (NYSE: INSP ) Immunovant Inc (NASDAQ: IMVT ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Laboratory Corp.
   The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO  2020/10/23 11:26:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Kodiak Sciences Inc (NASDAQ: KOD ) Nevro Corp (NYSE: NVRO ) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Repligen Corporation (NASDAQ: RGEN ) Replimune Group Inc (NASDAQ: REPL ) (priced its common stock offering of 4.69 million shares at $40 apiece. Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 22) Artelo Biosciences Inc (NASDAQ: ARTL ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Aziyo Biologics Inc (NASDAQ: AZYO ) DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its $15 million worth of common stock offering) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Metacrine Inc (NASDAQ: MTCR ) Rockwell Medical Inc (NASDAQ: RMTI ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Stocks In Focus Akebia Presents Positive Phase 3 Data For Anemia Drug In Chronic Kidney Disease Patients Akebia Therapeutics Inc (NASDAQ: AKBA ) presented at the American Society of Nephrology Kidney Week 2020 Reimagined, …
   SVB Leerink Weighs in on Replimune Group Inc’s FY2022 Earnings (NASDAQ:REPL)  2020/10/21 02:52:45 Stock Observer
Replimune Group Inc (NASDAQ:REPL) – Stock analysts at SVB Leerink cut their FY2022 EPS estimates for Replimune Group in a research note issued to investors on Wednesday, October 14th. SVB Leerink analyst J. Chang now forecasts that the company will earn ($2.04) per share for the year, down from their previous forecast of ($1.95). SVB […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 レプリミュ―ン REPL Replimune Group Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)